Lung cancer drug interaction study completed

NCT ID NCT02157883

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 19, 2025 · Last updated May 16, 2026 · Updated 23 times

Summary

This study looked at how the antifungal drug itraconazole changes the levels of the lung cancer drug AZD9291 in the body. It involved 39 adults with advanced EGFR-mutant non-small cell lung cancer whose disease had worsened after previous treatments. The goal was to understand the drug interaction, not to test a cure or symptom relief.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

San Diego, California, 92123, United States
Research Site

Cleveland, Ohio, 44106, United States
Research Site

Edegem, 2650, Belgium
Research Site

Ghent, 9000, Belgium
Research Site

Amsterdam, 1066 CX, Netherlands
Research Site

Maastricht, 6229 HX, Netherlands
Research Site

Rotterdam, 3015 GD, Netherlands
Research Site

lJongno-gu, 03080, South Korea
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Taipei, 10002, Taiwan
Research Site

Taipei, 11217, Taiwan
Research Site

London, SE1 9RT, United Kingdom
Research Site

Manchester, M20 4BX, United Kingdom

Conditions

Explore the condition pages connected to this study.

ADVANCED (INOPERABLE) NON SMALL CELL LUNG CANCER ADVANCED NON-SMALL CELL LUNG CANCER